HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I drugs for Cervical Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HF-158K1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HF-158K1 overview
HF-158K1 is under development for the treatment of HER2 expressing solid tumors (breast, bladder, pancreatic, ovarian, stomach, colon, prostate, lung, uterine and cervical cancers). It is a is a doxorubicin liposome that is being developed based on immunoliposome drug composites (iLDC) lipid technology. It is administered through intravenous route. It acts by targeting HER2 and topoisomerase II.
HighField Biopharmaceuticals overview
HighField Biopharmaceuticals is a drug R&D and production company focusing on the development of lipid drug technology. Highfield is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of HF-158K1’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
